B16-F10 melanoma-bearing mice treated with orlistat showed a reduction in the metastatic lymph node (LN) burden, as well as decreased VEGF-C and VEGFR-3 expression levels, thereby promoting an anti-lymphangiogenic phenotype15. This evidence concerns the gene VEGFC and melanoma.